| Literature DB >> 24835528 |
Stephen J Russell1, Mark J Federspiel2, Kah-Whye Peng2, Caili Tong2, David Dingli1, William G Morice3, Val Lowe4, Michael K O'Connor4, Robert A Kyle5, Nelson Leung6, Francis K Buadi5, S Vincent Rajkumar5, Morie A Gertz5, Martha Q Lacy5, Angela Dispenzieri7.
Abstract
MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression. Two measles-seronegative patients with relapsing drug-refractory myeloma and multiple glucose-avid plasmacytomas were treated by intravenous infusion of 10(11) TCID50 (50% tissue culture infectious dose) infectious units of MV-NIS. Both patients responded to therapy with M protein reduction and resolution of bone marrow plasmacytosis. Further, one patient experienced durable complete remission at all disease sites. Tumor targeting was clearly documented by NIS-mediated radioiodine uptake in virus-infected plasmacytomas. Toxicities resolved within the first week after therapy. Oncolytic viruses offer a promising new modality for the targeted infection and destruction of disseminated cancer.Entities:
Mesh：
Year: 2014 PMID： 24835528 PMCID： PMC4225126 DOI： 10.1016/j.mayocp.2014.04.003
Source DB: PubMed Journal: Mayo Clin Proc ISSN： 0025-6196 Impact factor: 7.616